Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bristol Myers Squibb's 3Q Revenues up 8% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Bristol Myers Squibb’s 3Q Revenues up 8%

Growth in the quarter was primarily driven by Eliquis, partially offset by generic erosion of Sprycel.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BMS
3Q Revenues: $11.9 billion (+8%)
3Q Earnings: $1.2 billion (-37%)
YTD Revenues: $35.96 billion (+7%)
YTD Loss: $9.0 billion (earnings were $6.3 billion 3Q23)
Comments: Growth in the quarter was primarily driven by Eliquis, partially offset by generic erosion of Sprycel due to the loss of exclusivity. Opdivo sales were up 4% to $2.4 billion in the quarter. Eliquis sales were $3.0 billion, up 11%. Revlimid sales were down 1% to $1.4 billion. Orencia sales were $936 million, up 1%. Pomalyst sales were up 3% to $898 million. Sprycel sales were down 44% to $290 million. Reblozyl sales were up 80% to $447 million. 
 
In the quarter, acquired IPRD increased to $262 million from $80 million and acquired intangible assets increased 7% to $2.4 billion, primarily due to the RayzeBio acquisition in 2024 and approval of Augtyro in the fourth quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters